Kailera Plans IPO for Obesity Drug That Could Top Lilly’s Zepbound (March 30, 2026) by Frank Vinluan Kailera Therapeutics’ planned IPO will fund ongoing clinical development of a pipeline led by a drug that could rival Eli Lilly’s Zepbound in both efficacy and tolerability. Meanwhile, Renaissance Capital’s recap of first quarter 2026 IPOs shows slowing activity amid market turbulence from

Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly (March 29, 2026) by Reuters In March 2026, Eli Lilly signed a global licensing deal worth up to $2.75 billion. The partnership utilizes Insilico’s AI platform to develop novel oral therapeutics, including a preclinical GLP-1 candidate for diabetes.Eli Lilly & Insilico Medicine: A $2.75 Billion Strategic AI-Driven Partnership Pharmaceutical companies

Drug developer Generate Biomedicines raises $400 million in US IPO (February 26, 2026) by Reuters Founded by Flagship in 2018, Generate Biomedicines uses AI-driven technology to move beyond traditional trial-and-error drug discovery and develop new protein-based therapies, with its pipeline centered on immunology and oncology. Generate’s lead drug candidate for severe asthma, GB-0895, is currently in a late-stage trial, with